Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979456 | 1.00 | SIGMAR1 (0.46) | SIGMAR1OPRL1 | |
| SCHEMBL4979627 | 0.90 | OPRM1 (0.42) | SIGMAR1OPRL1 | |
| SCHEMBL4979618 | 0.90 | OPRM1 (0.42) | SIGMAR1OPRL1 | |
| SCHEMBL4983412 | 0.88 | OPRL1 (0.49) | OPRL1 | |
| SCHEMBL4983419 | 0.88 | OPRL1 (0.49) | OPRL1 | |
| SCHEMBL4977604 | 0.87 | SIGMAR1 (0.42) | SIGMAR1OPRL1 | |
| SCHEMBL4977610 | 0.87 | SIGMAR1 (0.42) | SIGMAR1OPRL1 | |
| SCHEMBL4977401 | 0.84 | OPRL1 (0.39) | SIGMAR1OPRL1 | |
| SCHEMBL4977406 | 0.84 | OPRL1 (0.39) | SIGMAR1OPRL1 | |
| Citric Acid SCHEMBL4981576 | 0.81 | OPRL1 (0.45) | SIGMAR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468361-B2 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-12-23 | — | — | US | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080032956-A1 | 2-Ethyl and 2-Ethylidene-19-Nor-Vitamin D Compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7300925-B2 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070088008-A1 | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-19 | — | — | US | disclosed |
| US-7141558-B2 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCOUSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-11-28 | — | — | US | disclosed |
| US-6992074-B2 | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050282789-A1 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1524264-A2 | 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050043281-A1 | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-02-24 | — | — | US | disclosed |
| US-6806262-B2 | CELL DIFFERETIATION; SKIN AND BONE DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-10-19 | — | — | US | disclosed |
| US-20030013691-A1 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032956-A1 | 2-Ethyl and 2-Ethylidene-19-Nor-Vitamin D Compounds | CYP24A1, VDR, CYP2R1 | SIGMAR1 4700/4885OPRL1 3655/4885 |
| US-20050282789-A1 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | CYP24A1, VDR, CYP2R1 | SIGMAR1 4700/4885OPRL1 3655/4885 |
| US-20030013691-A1 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds | CYP24A1, VDR, CYP2R1 | SIGMAR1 4700/4885OPRL1 3655/4885 |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | SIGMAR1 10/4885OPRL1 1/4885 |
| US-20070088008-A1 | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds | CYP24A1, VDR, CYP2R1 | SIGMAR1 4700/4885OPRL1 3655/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | SIGMAR1 26/4885OPRL1 1/4885 |
| US-20050043281-A1 | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds | CYP24A1, VDR, CYP2R1 | SIGMAR1 4700/4885OPRL1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.